Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McMaster University
$105,000.00
Understanding the therapeutic potential of targeting bacterial ribosome biogenesis: a functional characterization of the Escherichia coli GTPase, YjeQ
FY 2010-11
Summary
Infectious diseases, caused by pathogenic microorganisms such as bacteria and viruses represent a significant threat to human health. Such diseases can be global in scope, affecting both the developing world and industrialized nations. The media coverage of the recent swine flu outbreaks highlights just how dramatically infectious disease can impact society; devastating human health and crippling economies. In recent years, global health care has been plagued by the emergence and dissemination of multi-drug resistant bacteria, the so-called 'super-bugs' that have rendered many of our most important antibiotics ineffective. Our most promising recourse lies in the development of novel antibiotics that target bacterial infections in new ways. Traditionally, antibiotics have targeted a narrow range of bacterial cell processes. A large proportion of our antibiotic arsenal works by directly interrupting the synthesis of proteins in bacteria by blocking translation, the cellular process by which the genetic code is interpreted to make proteins. Over time, bacteria have come up with multiple ways to circumvent drugs that directly inhibit this process. Translation is carried out by ribosomes, large molecules that mediate the interpretation of the genetic code. These cellular interpreters are absolutely required for protein synthesis in bacteria and thus, are necessary for life and pathogenesis. Like proteins, ribosomes themselves must also be synthesized. Disrupting the synthesis of ribosomes in turn blocks protein translation and ultimately inhibits bacterial growth. None of the antibiotics that we currently employ for therapeutic purposes work in this way. Thus, in targeting the synthesis of bacterial ribosomes we have an opportunity to develop new drugs that act by a mechanism not yet encountered by bacteria. Such a therapeutic strategy will give an edge to modern health care in the arms race against bacterial resistance.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
229618
Name
Stewart Geordie F
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Understanding the therapeutic potential of targeting bacterial ribosome biogenesis: a functional characterization of the Escherichia coli GTPase, YjeQ
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Antibiotic Drug Discovery; Biogenesis; Chromatography; Enzyme Kinetics; High-Throughput Screening; Nucelic Acid Biochemistry; Proteomics; Pulse-Chase; Ribosome; Translation
Abstract
Infectious diseases, caused by pathogenic microorganisms such as bacteria and viruses represent a significant threat to human health. Such diseases can be global in scope, affecting both the developing world and industrialized nations. The media coverage of the recent swine flu outbreaks highlights just how dramatically infectious disease can impact society; devastating human health and crippling economies. In recent years, global health care has been plagued by the emergence and dissemination of multi-drug resistant bacteria, the so-called 'super-bugs' that have rendered many of our most important antibiotics ineffective. Our most promising recourse lies in the development of novel antibiotics that target bacterial infections in new ways. Traditionally, antibiotics have targeted a narrow range of bacterial cell processes. A large proportion of our antibiotic arsenal works by directly interrupting the synthesis of proteins in bacteria by blocking translation, the cellular process by which the genetic code is interpreted to make proteins. Over time, bacteria have come up with multiple ways to circumvent drugs that directly inhibit this process. Translation is carried out by ribosomes, large molecules that mediate the interpretation of the genetic code. These cellular interpreters are absolutely required for protein synthesis in bacteria and thus, are necessary for life and pathogenesis. Like proteins, ribosomes themselves must also be synthesized. Disrupting the synthesis of ribosomes in turn blocks protein translation and ultimately inhibits bacterial growth. None of the antibiotics that we currently employ for therapeutic purposes work in this way. Thus, in targeting the synthesis of bacterial ribosomes we have an opportunity to develop new drugs that act by a mechanism not yet encountered by bacteria. Such a therapeutic strategy will give an edge to modern health care in the arms race against bacterial resistance.
Competitiondate
201010
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Stewart, Geordie F
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~